Advertisements


Dynavax reports interim data for study of SD-101 in combination Merck"s Keytruda

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 16th, 2018

Dynavax reports data for Phase 1b/2 trial of SD-101 in combination with Keytruda

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 4th, 2018

Bluebird Bio reports interim data from Phase 1 HGB-206 study of LentiGlobin

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 15th, 2018

Epizyme reports updated interim data from Phase 2 study of tazemetostat

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 15th, 2018

Merck"s Keytruda shows promise for melanoma

Merck said long-term data from its cancer drug Keytruda showed promise in treating advanced melanoma patients. Fred Katayama reports......»»

Category: videoSource: reutersJun 4th, 2018

Dynavax to present new SD-101 in combination with Keytruda data at ASCO

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMay 16th, 2018

Merck’s Bet on Cancer Immunotherapy Is Paying Off in Spades and Helping Lung Cancer Patients Live Longer

A combination of Merck's Keytruda and chemotherapy cut lung cancer death rates in half. New study results released Monday continue to cemen.....»»

Category: europeSource: fortuneApr 16th, 2018

Cellectar Biosciences reports "positive" Phase 2 interim data for CLR 131

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJul 18th, 2018

Catalyst announces "positive" interim data from study of Marzeptacog Alfa

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJul 18th, 2018

Xeris reports "positive" data from study of ready-to-use glucagon rescue pen

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 25th, 2018

Anika Reports Top Line Data from CINGAL Study, Shares Slump

Anika Therapeutics' (ANIK) shares declined 37%, after the company reported disappointing data from its phase III Cingal 16-02 study in treating patients with osteoarthritis (OA) in the knee. Sha.....»»

Category: smallbizSource: nytJun 21st, 2018

Anika Reports Top Line Data from CINGAL Study, Shares Slump

Zacks.....»»

Category: topSource: redinewsJun 21st, 2018

BeyondSpring expects to announce Phase 3 interim data for Study 105 in Q4

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 21st, 2018

Viveve reports six-month data from CMRF study to treat SUI in women

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 18th, 2018

Viveve reports positive 6-month data from stress urinary incontinence study

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 18th, 2018

Affimed Sinks Despite Positive Interim Results

Affimed N.V. (NASDAQ: AFMD) shares dropped sharply early on Friday after the firm released new results from its early stage trial with Keytruda. The firm presented new interim data from the Phase 1b........»»

Category: blogSource: 247wallstJun 15th, 2018

Affimed N.V. announces updated data of AFM13/Keytruda combination

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 15th, 2018

Alnylam Reports Positive Data on Lumasiran in Renal Disease

Alnylam (ALNY) announces positive results from the ongoing study on lumasiran in Primary Hyperoxaluria Type 1 (PH1) patients. Alnylam Ph.....»»

Category: smallbizSource: nytJun 11th, 2018

Nightstar Therapeutics Reports First Quarter 2018 Financial Results and Acceleration of Preliminary NSR-RPGR Readout to Third Quarter 2018

Preliminary data from dose escalation study in the Phase 1/2 XIRIUS trial for X-Linked Retinitis Pigm.....»»

Category: earningsSource: benzingaJun 6th, 2018

Merck Presents Positive Melanoma Data on Keytruda at ASCO

Merck (MRK) presents encouraging data from two pivotal advanced melanoma studies on its PD-L1 inhibitor, Keytruda. Merck & Co., .....»»

Category: personnelSource: nytJun 5th, 2018

Bristol-Myers (BMY) Reports Data from CheckMate-214 Study

Zacks.....»»

Category: topSource: redinewsJun 5th, 2018